Table 1. Active clinical trials of FTIs... | American Society of Hematology

Table 1.

Active clinical trials of FTIs in hematologic malignancies (as of June 2003)

Sponsor	Lead institution	Agent	Phase	Disease	Disease status	Endpoints
NCI	University of Maryland	R115777	2	AML, high-risk MDS	Untreated	Response rate, survival, FTase inhibition, angiogenesis, MAPK inhibition, AKT inhibition
NCI	University of Maryland	R115777	2	AML, MDS	After remission	Overall survival, disease-free survival
NCI	University of Chicago	R115777	1	Advanced hematologic malignancies	Refractory	Toxicity, FTase inhibition, clinical activity
NCI	NCI	R115777	1	Pediatric leukemias	Refractory	MTD, pharmacokinetics
NCI	Stanford University	R115777	1/2	Myeloproliferative disorders	Progressive	Toxicity, WBC response, erythroid response, cytogenetic response
MD Anderson	MD Anderson	R115777 + imatinib mesylate	1	CML	Chronic-phase, imatinib failure	MTD, toxicity
Johnson & Johnson	International	R115777	2	AML	Post-remission	Overall survival, disease-free survival
Johnson & Johnson	National	R115777	2	High-risk MDS	1 or fewer prior therapy	Response rate, toxicity
Schering-Plough	National	SCH66336	1/2	AML, CML, ALL, MDS	3 or fewer prior therapies	Safety and tolerability, pharmacokinetics, FTase inhibition, clinical activity

Sponsor	Lead institution	Agent	Phase	Disease	Disease status	Endpoints
NCI	University of Maryland	R115777	2	AML, high-risk MDS	Untreated	Response rate, survival, FTase inhibition, angiogenesis, MAPK inhibition, AKT inhibition
NCI	University of Maryland	R115777	2	AML, MDS	After remission	Overall survival, disease-free survival
NCI	University of Chicago	R115777	1	Advanced hematologic malignancies	Refractory	Toxicity, FTase inhibition, clinical activity
NCI	NCI	R115777	1	Pediatric leukemias	Refractory	MTD, pharmacokinetics
NCI	Stanford University	R115777	1/2	Myeloproliferative disorders	Progressive	Toxicity, WBC response, erythroid response, cytogenetic response
MD Anderson	MD Anderson	R115777 + imatinib mesylate	1	CML	Chronic-phase, imatinib failure	MTD, toxicity
Johnson & Johnson	International	R115777	2	AML	Post-remission	Overall survival, disease-free survival
Johnson & Johnson	National	R115777	2	High-risk MDS	1 or fewer prior therapy	Response rate, toxicity
Schering-Plough	National	SCH66336	1/2	AML, CML, ALL, MDS	3 or fewer prior therapies	Safety and tolerability, pharmacokinetics, FTase inhibition, clinical activity

NCI indicates National Cancer Institute; WBC, white blood cell.